Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

PHASE3CompletedINTERVENTIONAL
Enrollment

517

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

June 8, 2022

Study Completion Date

June 29, 2022

Conditions
Alopecia Areata
Interventions
DRUG

CTP-543 matching placebo

Administered as tablets.

DRUG

CTP-543

Administered as tablets.

Trial Locations (63)

1085

Semmelweis Egyetem, Általános Orvostudományi Kar, Bőr-, Nemikórtani És Bőronkológiai Klinika, Budapest

3200

Bugát Pál Kórház, Gyöngyös

6720

Szte Áok Szent-Györgyi Albert Klinikai Központ Bőrgyógyászati És Allergológiai Klinika, Szeged

7632

Pécsi Tudományegyetem Klinikai Központ, Bőr-, Nemikórtani És Onkodermatológiai Klinika, Pécs

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center - Department of Dermatology, New York

10117

Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin, Berlin

14004

Hospital Universitario Reina Sofia, Córdoba

14642

University of Rochester, Rochester

22903

The Rector and Visitors of the University of Virginia, Charlottesville

28034

Hospital Universitario Ramón Y Cajal - Edificio Consultas Externas, Madrid

28041

Hospital Doce de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

28081

Hospital Universitario Infanta Leonor, Madrid

33124

University of Miami Hospital, Miami

33145

Floridian Research Institute LLC, Miami

37922

The Skin Wellness Center, Knoxville

44791

Dermatologische Studienambulanz, Bochum

45040

Dermatologists of Southwest Ohio, Mason

48059

Hamzavi Dermatology, Fort Gratiot

48087

Clinical Research Institute of Michigan, LLC, Chesterfield

48149

University Hospital Muenster, Münster

48455

Fachklinik Bad Bentheim - Dermatologische Studienambulanz, Bad Bentheim

60590

Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie, Frankfurt am Main

63005

Galen Research, Chesterfield

72076

Universitaetsklinikum Tübingen, Tübingen

72916

Johnson Dermatology, Fort Smith

75034

North Texas Center for Clinical Research, Frisco

77077

Elixir Research Group, Houston

78213

Progressive Clinical Research, San Antonio

80802

Klinikum Rechts Der Isar, Technische Universität München, Munich

84095

Jordan Valley Dermatology Center, South Jordan

84101

Velocity Clinical Research/Gateway, Salt Lake City

84117

Velocity Clinical Research/Swinyer-Woseth Dermatology, Salt Lake City

85032

Alliance Dermatology & Mohs Center, Phoenix

89148

Vivida Dermatology, Las Vegas

90045

Dermatology Research Associates, Los Angeles

91054

Universitätsklinikum Erlangen Hautklinik, Erlangen

97223

Oregon Medical Research, Portland

02135

MetroBoston Clinical Partners, LLC, Brighton

07044

The Dermatology Group P.C., Verona

02886

Velocity Clinical Research - Providence, Warwick

T4N6V7

Care Clinic Ltd., Red Deer

V1Y 4N7

Medical Arts Health Research Group, Kelowna

M8X1Y9

Kingsway Clinical Research, Etobicoke

P1B 3Z7

North Bay Dermatology Centre, North Bay

L4B1A5

The Centre for Dermatology, Richmond Hill

Centre de Recherche Dermatologique du Quebec Metropolitan, Québec

G1W4R4

Centre de Recherche Saint-Louis, Québec

06202 CEDEX 3

Centre Hospitalier Universitaire de Nice - Hôpital Archet 2, Nice

29609 CEDEX

Chru de Brest - Hôpital Morvan, Brest

50-685

Wromedica I. Bielicka, A. Strzalkowska S.C., Wroclaw

67-100

Twoja Przychodnia - Centrum Medyczne Nowa Sól, Nowa Sól

08-110

Etg Siedlce, Siedlce

00-716

Ot.Co Clinic Klinika Osipowicz & Turkowski Sp. Z O.O., Warsaw

00-892

Rcmed Oddzial Warszawa, Warsaw

02-664

Carpe Diem Centrum Medycyny Estetycznej, Warsaw

02-793

Etg Warszawa, Warsaw

71-434

Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin

96-100

Etg Skierniewice, Skierniewice

08001

Hospital Del Mar, Barcelona

08041

Hospital Santa Creu I Sant Pau, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY

NCT04797650 - Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) | Biotech Hunter | Biotech Hunter